Pain Treatment in Bladder Pain Syndrome



Patients with bladder pain syndrome (BPS) often present with poorly defined symptoms and significant psychological changes. Current understanding suggests that BPS may involve changes in neural processing which results in chronic pain of visceral origin. These pains are therefore considered as neuropathic. With limited research into the specific management of BPS the treatments used tend to be those used for other neuropathic pains.

The management of BPS involves a multidisciplinary approach with contributions from various specialties including, urology, gynaecology, gastroenterology, psychology, physiotherapy, genitourinary medicine and pain medicine.

Further research is needed to understand the pathophysiology and pain pathways involved which will in turn help in the management of these patients. Medical treatment involves the use of drugs that target receptors in the pain pathway. When conservative management fails, the use of interventional procedures may be considered.


Chronic Pain Neuropathic Pain Central Sensitisation Transcutaneous Electrical Nerve Stimulation Reflex Sympathetic Dystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Buffington CAT. Comorbidity of interstitial cystitis with other unexplained clinical conditions. J Urol. 2004;172(4 Pt 1):1242–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Buffington CAT. Bladder pain syndrome/interstitial cystitis—etiology and animal research. In: Baranowski AP, Abrams P, Fall M, editors. Urogenital pain in clinical practice. Informa healthcare, 2008, New York, ISBN-10:0-8493-9932-7 p. 169–83.Google Scholar
  3. 3.
    Baranowski AP, Abrams P, Berger RE, et al. Urogenital pain–time to accept a new approach to phenotyping and, as a consequence, management. Eur Urol. 2008;53(1):60–7.CrossRefGoogle Scholar
  4. 4.
    Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57:35–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Bannworth B, Pehourq F. Pharmacologic basis for using paracetemol: pharmacokinetic and pharmacodynamic issues. Drugs. 2003;63: Spec No 2:5–13.Google Scholar
  6. 6.
    Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal anti-inflammatory drug or pure analgesic. J Rheumatol. 1992;19(12):1950–4.PubMedGoogle Scholar
  7. 7.
    Temple AR, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28(2):222–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Bianchi M, Panerai AE. The dose-related effects of paracetamol on hyperalgesia and nociception in the rat. Br J Pharmacol. 1996;117:130–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Koppert W, Wehrfritz A, Körber N, Sittl R, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 2004;108(1–2):148–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Fitzgerald G. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17):1709–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev. 2003;(4):CD001751.Google Scholar
  12. 12.
    Saarto T, Wiffen P. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81:1372–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Phatak S, Foster Jr HE. The management of interstitial cystitis: an update. Nat Clin Pract Urol. 2006;3:45–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging. 2003;20(15):1111–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Chew DJ, Buffington CA, Kendall MS, DiBartola SP, Woodworth BE. Amitriptyline treatment for severe recurrent idiopathic cystitis in cats. J Am Vet Med Assoc. 1998;213(9):1282–6.PubMedGoogle Scholar
  16. 16.
    Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;(4):CD007115.Google Scholar
  18. 18.
    Neuropathic pain. National Institute of Health and Clinical Excellence. Clinical Guideline 96. Published March 2010.
  19. 19.
    Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD001133.Google Scholar
  20. 20.
    Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.Google Scholar
  21. 21.
    Price DD, Mayer DJ, Mao J, Caruso FS. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage. 2000;19(1 Suppl):S7–S11.PubMedCrossRefGoogle Scholar
  22. 22.
    Eide PK, Jørum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-d-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 1994;58(3):347–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Guirimand F, Dupont X, Brasseur L, Chauvin M, et al. The effects of ketamine on the temporal summation (wind-up) of the RIII nociceptive flexion reflex and pain in humans. Anesth Analg. 2000;90:408–14.PubMedGoogle Scholar
  24. 24.
    Laurido C, Pelissier T, Pérez H, Flores F, et al. Effect of ketamine on spinal cord nociceptive transmission in normal and monoarthritic rats. Neuroreport. 2001;12(8):1551–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Mikkelsen S, Ilkjaer S, Brennum J, Borgbjerg F, et al. The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology. 1999;90(6):1539–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2010;14(5):466–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract. 2011;65(1):27–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Wood D, Cottrell A, Baker SC, et al. Recreational ketamine: from pleasure to pain. BJU Int. 2011;107:1881–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Cummins T, Sheets P, Waxman S. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131(3):243–57.PubMedCrossRefGoogle Scholar
  31. 31.
    Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17(6):429–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage. 1996;12(3):161–7.PubMedCrossRefGoogle Scholar
  33. 33.
    McQuay H. Opioids in pain management. Lancet. 1999;353(9171):2229–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;3:CD006146.Google Scholar
  35. 35.
    Sagata K, Minami K, Yanagihara N, Shiraishi M, et al. Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002;94(4):901–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol. 1996;41(1):7–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2006;3:CD003726.Google Scholar
  38. 38.
    Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13–21.PubMedGoogle Scholar
  39. 39.
    Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O. Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects. Eur J Pain. 2007;11(6):599–604.PubMedCrossRefGoogle Scholar
  40. 40.
    Kalso E, Allan L, Dellemijn PL, Faura CC, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7(5):381–6.PubMedCrossRefGoogle Scholar
  41. 41.
    The British Pain Society. Opioids for persistent pain: Good practice. London: The British Pain Society; 2010.
  42. 42.
    Fall M, Lindström S. Transcutaneous electrical nerve stimulation in classic and nonulcer interstitial cystitis. Urol Clin North Am. 1994;21(1):131–9.PubMedGoogle Scholar
  43. 43.
    Kemler MA, Barendse GAM, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 2000;343:618–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Pinto R, Lopes T, Frias B, Silva A, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Pain Management UnitThe James Cook University HospitalMiddlesbroughUK
  2. 2.Anaesthesia, Intensive Care and Pain Medicine, Pain Management UnitThe James Cook University HospitalMiddlesbroughUK

Personalised recommendations